
BOLD CLINICAL TRIALS
One DES head-to-head trial.
Zero doubt.
Bold is being the first company to conduct Level-1 head-to-head comparative effectiveness trials directly comparing drug-eluting technologies. Regardless of patient or lesion complexity, Eluvia DES has durable and consistent results. See how it can make a difference in the fight against PAD.

NEXT-GENERATION TECHNOLOGY
Built for sustained drug release and efficient drug transfer.
Only the Eluvia™ Drug-Eluting Stent offers sustained drug release to match the restenotic process in the SFA, with the lowest drug-dose2 delivered by the most proven polymer.
Available now in 150mm length, the Eluvia 150 is the longest DE SFA stent for complex lesions.
Clinical Highlights
EMINENT Randomized Controlled Trial Results3
Eluvia DES demonstrated superior primary patency4 over bare metal stents through 1-Year in the world's largest RCT of SFA stents.

**Log-rank p-value compares the entire K-M curves from time point zero to day 395 (full 1-year follow-up window)
1. 92.1% K-M Primary Patency. Gray W. 2-year Outcomes from the IMPERIAL Randomized Head to Head Study of Eluvia DES and Zilver PTX; LINC 2020, Leipzig Jan 28,2020.
2. Drug Dose Data from Eluvia DES, Zilver PTX, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB and Ranger DCB Instructions for Use. Data on file at Boston Scientific. Represents total global sales of the PROMUS (Boston Scientific) and XIENCE (Abbott) stents since 2006.
3. EMINENT RCT 1-Year results presented by Yann Gouëffic, MD. VIVA 2021.
4. EMINENT Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against commercially-available Self-Expanding Bare Nitinol Stents, single-blind, superiority design; independent core lab adjudication. Primary Endpoint: 1-Year Binary Primary Patency rate of 83.2% in the Eluvia arm vs. 74.3% in the Bare-Metal Stenting arm (p-value = 0.0077).

RESTENOSIS REPLACEMENT PROGRAM
Standing together.
The Bold Step Program is a statement of our confidence in the efficacy of our drug-eluting products. The program offers an Eluvia DES or Ranger DCB at no additional charge if a patient requires reintervention within the first year due to restenosis.

Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.
